Keywords: GlaxoSmithKline, Theravance, Relovair, Regulatory filings, USA, Europe, Asthma, COPD, Advair, Ph III progams
Relovair COPD and asthma filings on track despite more mixed trial results
Article | 26 March 2012
As well as announcing new mixed clinical trial data, UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
